相关实验视频
Updated: May 10, 2026

Establishment and Characterization of UTI and CAUTI in a Mouse Model
Published on: June 23, 2015
基于结构的设计,一种免疫原性,形状稳定的FimH抗原用于尿路感染疫苗
Natalie C Silmon de Monerri1, Ye Che2, Joshua A Lees2
1Vaccine Research and Development, Pfizer Inc, Pearl River, New York, New York, United States of America.
开发了一种新的哺乳动物细胞生产方法和FimH蛋白的计算设计,产生了针对尿路感染 (UTI) 的有效疫苗候选者. 这种改进的FimH变种阻断了细菌粘附,并引起了保护性抗体,推动了尿路感染疫苗的开发.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 结构生物学 结构生物学
背景情况:
- 尿路感染 (UTI) 往往是由大肠杆菌通过FimH粘附在尿路上皮上粘附引起的.
- FimH (Fimbrial protein H) 是尿路感染疫苗的关键目标,但其发展受到生产和免疫性挑战的限制.
- 以前在大肠杆菌中进行复合FimH生产遇到了困难,阻碍了有效的疫苗候选人的开发.
研究的目的:
- 开发一种基于哺乳动物细胞的新型生产方法,用于高产量,均的FimH蛋白.
- 通过计算设计和评估稳定,更具免疫性的FimH突变体.
- 为了确定FimH向抗体的新型表位,与尿路感染疫苗策略相关.
主要方法:
- 哺乳动物细胞表达系统用于复合FimH生产.
- 计算式蛋白质设计以优化FimH稳定性和免疫性.
- 用于结构分析的X射线晶体学和冷电子显微镜.
- 细菌粘附抑制试验和小鼠免疫性研究.
主要成果:
- 一种新的哺乳动物细胞生产方法产生了大量同质的FimH蛋白.
- 计算设计的FimH变体 (FimH-DSG TM) 显示出增强的稳定性和免疫性,阻断细菌粘附.
- 结构分析证实了稳定FimH变种与本地FimH的相似性.
- 对FimH-DSG TM抗体的表征确定了新的抑制表位和结合部位.
结论:
- 开发的哺乳动物生产系统和FimH变种为有效的尿路感染疫苗提供了有希望的战略.
- 鉴定新型抑制性表位物为设计FimH导向抗体提供了关键的见解.
- 这项工作推动了针对FimH的疫苗的开发,以预防大肠杆菌介导的尿路感染.
更多相关视频
00:10Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
13:53Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
相关概念视频
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Vaccinations
Immunofluorescence Microscopy
The...
Microorganisms in Medicine and Therapeutics
Fimbriae, Pili, and Axial Filaments
Vaccines